[On clinical evaluation of the effect of azapropazon, a new anti-inflammatory agent, in diseases of the rheumatic group].
D000208:Acute Disease; D000328:Adult; D000893:Anti-Inflammatory Agents / Q000627:therapeutic use*; D002908:Chronic Disease; D004361:Drug Tolerance; D004551:Elbow Joint; D005260:Female; D006073:Gout / Q000188:drug therapy; D006618:Hip Dislocation, Congenital / Q000188:drug therapy; D006801:Humans; D007592:Joint Diseases / Q000188:drug therapy; D008297:Male; D008875:Middle Aged; D011111:Polymyalgia Rheumatica / Q000188:drug therapy; D012019:Reflex Sympathetic Dystrophy / Q000188:drug therapy; D012216:Rheumatic Diseases / Q000188:drug therapy*; D052256:Tendinopathy / Q000188:drug therapy; D013717:Tenosynovitis / Q000188:drug therapy; D013924:Thrombophlebitis / Q000188:drug therapy; D014227:Triazines / Q000009:adverse effects / Q000627:therapeutic use*
D000893:Anti-Inflammatory Agents; D014227:Triazines
Zur klinischen Beurteilung der Wirkung von Azapropazon, einem neuen Antiphologisticum, bei Erkankungen des rheumatischen Formenkreises.